2-(4-(BROMOMETHYL)PHENYL)OXAZOLE
- $266 - $2000
- Product name: 2-(4-(BROMOMETHYL)PHENYL)OXAZOLE
- CAS: 866261-56-5
- MF: C10H8BrNO
- MW: 238.08
- EINECS:
- MDL Number:MFCD19382388
- Synonyms:2-(4-(BROMOMETHYL)PHENYL)OXAZOLE;Oxazole, 2-[4-(bromomethyl)phenyl]-;2-[4-(bromomethyl)phenyl]-1,3-oxazole
5 prices
Selected condition:
Brand
- AK Scientific
- AstaTech
- Crysdot
Package
- 250mg
- 1g
- 0.25/ G
- 1/ G
- 5/ G
- ManufacturerAK Scientific
- Product number3647CZ
- Product description2-(4-(Bromomethyl)phenyl)oxazole
- Packaging250mg
- Price$411
- Updated2021-12-16
- Buy
- ManufacturerAstaTech
- Product number52427
- Product description2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95%
- Packaging5/ G
- Price$2000
- Updated2021-12-16
- Buy
- ManufacturerAstaTech
- Product number52427
- Product description2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95%
- Packaging1/ G
- Price$667
- Updated2021-12-16
- Buy
- ManufacturerAstaTech
- Product number52427
- Product description2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95%
- Packaging0.25/ G
- Price$266
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11041121
- Product description2-(4-(Bromomethyl)phenyl)oxazole 97%
- Packaging1g
- Price$396
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 3647CZ | 2-(4-(Bromomethyl)phenyl)oxazole | 250mg | $411 | 2021-12-16 | Buy |
AstaTech | 52427 | 2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95% | 5/ G | $2000 | 2021-12-16 | Buy |
AstaTech | 52427 | 2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95% | 1/ G | $667 | 2021-12-16 | Buy |
AstaTech | 52427 | 2-(4-(BROMOMETHYL)PHENYL)OXAZOLE 95% | 0.25/ G | $266 | 2021-12-16 | Buy |
Crysdot | CD11041121 | 2-(4-(Bromomethyl)phenyl)oxazole 97% | 1g | $396 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|